Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Integra Lifesciences ( (IART) ) has provided an announcement.
Integra LifeSciences held its 2026 Annual Meeting of Stockholders on May 7, 2026, where shareholders approved Amendment No. 3 to the company’s Fifth Amended and Restated 2003 Equity Incentive Plan, adding 3,550,000 shares of common stock for future equity awards. All nominated directors were elected to serve until the 2027 annual meeting, and shareholders ratified PricewaterhouseCoopers LLP as the independent auditor for the 2026 fiscal year while giving advisory approval to the executive compensation program, signaling continued investor support for the company’s leadership and long-term incentive strategy.
The most recent analyst rating on (IART) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Integra Lifesciences stock, see the IART Stock Forecast page.
Spark’s Take on IART Stock
According to Spark, TipRanks’ AI Analyst, IART is a Neutral.
The score is held back primarily by the severe 2025 financial deterioration (revenue collapse, large losses, and weakened free cash flow) and an unattractive earnings-based valuation (negative P/E). Offsetting these are a relatively constructive latest earnings update (beats, margin expansion, and raised adjusted EPS guidance) and modestly improving near-term technicals, though the stock remains below longer-term moving averages.
To see Spark’s full report on IART stock, click here.
More about Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company focused on developing and manufacturing surgical, neurosurgical and regenerative care products. The company serves hospitals and healthcare providers with devices and solutions aimed at improving patient outcomes in specialized clinical areas and maintains a significant presence in the global medtech market.
Average Trading Volume: 903,910
Technical Sentiment Signal: Sell
Current Market Cap: $1.05B
Learn more about IART stock on TipRanks’ Stock Analysis page.